# OnCo record burkitt-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/burkitt-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "burkitt-lymphoma" ;
  schema:name "Burkitt lymphoma"@en ;
  schema:alternateName "Burkitt lymphoma/leukaemia"@en, "Endemic Burkitt lymphoma"@en, "Sporadic Burkitt lymphoma"@en, "Immunodeficiency-associated Burkitt lymphoma"@en ;
  schema:description "Burkitt lymphoma is the fastest-growing human tumour, driven by a single rearrangement that switches on the MYC gene. That speed makes it exquisitely sensitive to chemotherapy: short, intense courses, now with the antibody rituximab, cure the great majority of children in well-resourced settings. The remaining task is to bring the same cure to the African children who make up most cases."@en ;
  schema:url <https://onco.cc/cancers/burkitt-lymphoma/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Burkitt_lymphoma> ;
  schema:citation <https://www.cancer.gov/types/lymphoma/hp/child-nhl-treatment-pdq>, <https://doi.org/10.1056/NEJMoa1915315>, <https://doi.org/10.1002/pbc.24407> ;
  onco:tag "nci-coverage", "paediatric", "haematologic", "global-health" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hiv-associated-lymphoma/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/global-oncology-access/>, <https://onco.cc/technologies/cytogenetics-fish/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/etoposide/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:institutions <https://onco.cc/institutions/siop-europe/>, <https://onco.cc/institutions/uganda-cancer-institute/> ;
  onco:pathways <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/pathways/bcr-signalling/> ;
  onco:terms <https://onco.cc/terms/tumor-lysis-syndrome/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/lymphoma-type/> ;
  onco:trials <https://onco.cc/trials/inter-b-nhl-ritux-2010/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-minard-colin-n-engl-j-med/>, <https://onco.cc/key-papers/paper-hesseling-pediatr-blood-cancer/> ;
  onco:pipeline <https://onco.cc/trials/inter-b-nhl-ritux-2010/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/global-oncology-access/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/trials/inter-b-nhl-ritux-2010/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/technologies/global-oncology-access/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/car-t/> .